Antibodies to lymphotoxin-α
AssigneeGenetech, Inc.
InventorsCamellia W. Adams, Jane L. Grogan, Austin L. Gurney, Krista McCutcheon
Life of this patent
Estimating the term…
Abstract
The invention provides various antibodies that bind to lymphotoxin-α, methods for making such antibodies, compositions and articles incorporating such antibodies, and their uses in treating, for example, an autoimmune disorder. The antibodies include murine, chimeric, and humanized antibodies.
Claims64
An isolated anti-lymphotoxin-α (LTα) antibody comprising a light chain variable region wherein the complementarity-determining region (CDR)-L1 sequence is KSSQSLLYSTXQKXFLA (SEQ ID NO:3) or KSSQSLLYSAXQKXFLA (SEQ ID NO:4) or KSSQSLLYSTXQKXALA (SEQ ID NO:6), where X is any amino acid;
- the CDR-L2 sequence is WASTRDS (SEQ ID NO:8);
- the CDR-L3 sequence is QQYYSYPRT (SEQ ID NO:13) or QQYASYPRT (SEQ ID NO:14) or QQYYAYPRT (SEQ ID NO:15), and a heavy chain variable region wherein the CDR-H1 sequence is GYTFSSYWIE (SEQ ID NO:17);
- the CDR-H2 sequence is EISPGSGSTXYXEEFKG (SEQ ID NO:19) or EIXPGSGSTIYXEKFKG (SEQ ID NO:110), wherein X is any amino acid;
- and the CDR-H3 sequence is GYHGY (SEQ ID NO:21) or GYHGA (SEQ ID NO:22).
An isolated anti-lymphotoxin-α (LTα) antibody comprising a light chain variable region wherein complementarity-determining region (CDR)-L1 comprises amino acids 24-40 of SEQ ID NO:
- 108, CDR-L2 comprises amino acids 56-62 of SEQ ID NO:
- 108, and CDR-L3 comprises amino acids 95-103 of SEQ ID NO:
- 108, and a heavy chain variable region wherein CDR-H1 comprises amino acids 26-35 of SEQ ID NO:
- 109, CDR-H2 comprises amino acids 50-66 of SEQ ID NO:
- 109, and CDR-H3 comprises amino acids 99-103 of SEQ ID NO:
- 109.
Dependencies are inferred from the claim text.